Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PMGC Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PMGC Holdings's position in the market.
NorthStrive Biosciences (Nasdaq: ELAB) filed ten U.S. patent applications on Feb. 19, 2026, extending its EL-22 and EL-32 technologies into animal health and agricultural markets.
The filings cover muscle growth and yield in livestock and poultry, aquaculture growth and emissions reduction, and list ten U.S. application numbers for EL-22 and EL-32.
NorthStrive Biosciences (NASDAQ: ELAB) executed a definitive, exclusive license agreement with Modulant Biosciences for its EL-22 and EL-32 myostatin-engineered probiotic programs for non-human animal health (worldwide excluding the Republic of Korea).
The License grants Modulant exclusive, royalty-bearing, sublicensable rights to develop, manufacture, and commercialize products from issued patents, pending applications, and know-how; Modulant assumes development, regulatory, manufacturing, and commercialization responsibilities while the agreement excludes any human pharmaceutical applications.
NorthStrive Biosciences (NASDAQ:ELAB) updated the Phase III timeline for its AI development program with strategic partner Yuva Biosciences. Phase III was initiated on December 17, 2025 and initially expected to last ~6–9 weeks. Upgraded sixth‑generation classifier models improve screening accuracy, and Yuva now expects Phase III results in Q2 2026. NorthStrive notes it does not control Yuva’s timeline and results remain subject to change.
PMGC Holdings (NASDAQ: ELAB) completed the acquisition of SVM Machining, a Northern California ISO 9001:2015 certified CNC precision machining firm. PMGC purchased 100% of SVM on a cash-free, debt-free basis for a $2.25M base price with a $250,000 indemnification holdback and earnout potential. SVM reported $3,042,701 revenue for the fiscal year ended December 31, 2024. The deal expands PMGC’s multi-site precision manufacturing platform across aerospace, defense, medical, semiconductor, biotech, and transportation markets.
PMGC Holdings (NASDAQ: ELAB) announced that its investment arm PMGC Capital acquired a non-controlling equity stake in Nuclea Energy, a company developing Micro Modular Reactors (MMR). The transaction closed on November 6, 2025.
The move aligns with PMGC Capital's focus on next-generation energy infrastructure, energy security, and decarbonization. The release cites a projected global SMR/MMR market growth from about $7.5 billion in 2025 to more than $16 billion by 2034, a ~9% CAGR, and notes demand drivers including grid stability, industrial loads, and data centers.
PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-4 reverse stock split of its common stock effective Jan 6, 2026 at 9:00 AM ET. Every four issued or authorized shares will be consolidated into one share, with fractional-share holders receiving one full share for each fractional portion.
The trading symbol remains ELAB and the new CUSIP is 73017P409. Outstanding equity awards, options, reserved shares, and warrants and their exercise prices will be proportionally adjusted. Immediately prior to the split the company had approximately 2,014,852 issued and outstanding shares; following the split it expects about 503,713 shares outstanding, subject to customary rounding and adjustments. Certificate holders can exchange through VStock Transfer.
PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-4 reverse stock split of its common stock at 9:00 AM ET on January 6, 2026. Every four issued or authorized shares will be consolidated into one share and fractional entitlements will be converted into whole shares.
The trading symbol will remain ELAB and the company will use a new CUSIP 73017P409. Outstanding awards, options, reserved shares, and warrant shares and exercise prices will be adjusted proportionally. Transfer agent VStock Transfer will handle certificate exchanges.
The company expects approximately 2,034,882 shares outstanding immediately prior to the split and about 508,721 shares outstanding immediately following the split.
PMGC Holdings (Nasdaq: ELAB) said its subsidiary AGA Precision Systems achieved AS9100 certification on Dec. 22, 2025, the quality management standard for aerospace, defense and space manufacturing.
The company says AS9100 confirms a structured, process-based quality system that may enable AGA to support more complex, regulated programs and deepen relationships with existing aerospace, defense and space customers, potentially driving increased demand and recurring work. The company is also researching integration of humanoid robotics and advanced robotic automation into manufacturing, but noted these initiatives are under evaluation with no assurance they will occur or deliver expected benefits.
NorthStrive Biosciences (NASDAQ:ELAB) initiated Phase III of its AI Development Program with Yuva Biosciences to move AI-prioritized small-molecule candidates into experimental validation targeting muscle preservation via mitochondrial function.
Phase III will generate biological data including cytotoxicity screening and ANT1 expression testing at multiple timepoints, leveraging an exclusive mitochondrial biogenesis dataset and YuvaBio’s MitoNova™ AI classifier to focus testing on the most promising candidates. The work is intended to accelerate discovery and reduce compounds advanced for further development. Phase III is expected to take approximately 6 to 9 weeks.
PMGC Holdings (NASDAQ: ELAB) congratulated General Enterprise Ventures (NYSE American: CITR) on its uplisting to the NYSE American on December 4, 2025 and highlighted PMGC Capital's equity investment in GEVI.
PMGC said the uplisting should increase GEVI's visibility and access to institutional capital as it scales CitroTech, an EPA Safer Choice and UL GreenGuard Gold certified, non‑toxic fire‑inhibition technology with 80+ global patents and 18+ environmental accreditations. Target markets include commercial/industrial protection, lumber treatment, energy storage systems, transportation, defense, and wildfire mitigation.